Resolving post-investment risk at a pharmaceutical distributor
Anonymised case · Professional reference
Background and challenges
After investing in a pharmaceutical distribution services company, an investment institution found significant discrepancies between reported operations, cash flow and market performance. The authenticity of the business was in doubt and fund flows were unclear. Without a robust evidence base, the investor faced a major risk of asset impairment.
Approach and implementation
The team followed a process of in-depth data analysis, evidence preservation and strategic negotiation. Industry data models, cross-checks with upstream and downstream parties, and discreet due diligence clarified actual business conditions and fund flows. Guided by judicial evidentiary requirements, the team preserved business inconsistencies, abnormal transactions and related-party information as legally usable evidence, then conducted multiple rounds of negotiations with founders, shareholders and other responsible parties on the investor's behalf.
Outcomes
The parties reached a comprehensive settlement and compensation agreement. The investor recovered substantial potential losses and obtained additional compensation for the use of its funds, resolving the overall investment risk efficiently and thoroughly.
Lessons for international cooperation and governance
The approach offers reference for cross-border investment and post-investment oversight of international pharmaceutical and medical-device distribution, combining multi-jurisdictional due diligence, cross-border evidence preservation and international commercial negotiation.